Serving hundreds of leading biopharmaceutical companies globally:

Generated: November 18, 2018

DrugPatentWatch Database Preview

King Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There are six US patents protecting KING PHARMS drugs.

Summary for King Pharms

US Patents:	6
Tradenames:	25
Ingredients:	23
NDAs:	27

Drugs and US Patents for King Pharms

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms	CYTOMEL	liothyronine sodium	TABLET;ORAL	010379-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-001	Jan 28, 1991	AB	RX	Yes	No	7,368,469	➤ Sign Up				➤ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-002	May 25, 2001	AB1,AB3	RX	Yes	No	7,101,569	➤ Sign Up				➤ Sign Up
King Pharms Llc	BICILLIN L-A	penicillin g benzathine	INJECTABLE;INJECTION	050141-001	Approved Prior to Jan 1, 1982	BC	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
King Pharms	CYTOMEL	liothyronine sodium	TABLET;ORAL	010379-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No		➤ Sign Up				➤ Sign Up
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-008	May 25, 2001	AB1,AB3	RX	Yes	No	7,067,148	➤ Sign Up	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for King Pharms

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	TILADE	nedocromil sodium	AEROSOL, METERED;INHALATION	019660-001	Dec 30, 1992	4,474,787	➤ Sign Up
King Pharms Llc	INTAL	cromolyn sodium	SOLUTION;INHALATION	018596-001	May 28, 1982	3,975,536	➤ Sign Up
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-004	Jan 28, 1991	4,587,258	➤ Sign Up
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-004	Jan 28, 1991	5,403,856	➤ Sign Up
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-002	Jan 28, 1991	5,061,722	➤ Sign Up
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	3,935,267	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for KING PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	30 mg, 60 mg, 90 mg and 120 mg	➤ Subscribe	2007-06-04
➤ Subscribe	Tablets	800 mg	➤ Subscribe	2004-11-04
➤ Subscribe	Extended-release Capsules	45 mg and 75 mg	➤ Subscribe	2009-07-30

International Patents for King Pharms Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
China	1268331	➤ Sign Up
Mexico	PA03007337	➤ Sign Up
Norway	20033637	➤ Sign Up
Mexico	PA03007332	➤ Sign Up
Serbia	50377	➤ Sign Up
European Patent Office	1216038	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for King Pharms Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB98/047	United Kingdom	➤ Sign Up	PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
C0062	France	➤ Sign Up	PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C0001	Belgium	➤ Sign Up	PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
13/055	Ireland	➤ Sign Up	PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
80030	Netherlands	➤ Sign Up	PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
323	Luxembourg	➤ Sign Up	PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim

Harvard Business School

Johnson and Johnson

AstraZeneca

Chinese Patent Office

Cantor Fitzgerald

Fuji

Daiichi Sankyo

QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.